^
    Apply
    A Study of SEA-CD40 Given With Other Drugs in Cancers (KEYNOTE-C86) (NCT04993677)
    Phase 2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    01/22/2025
    Initiation :
    10/06/2021
    Primary completion :
    01/03/2024
    Completion :
    10/31/2025
    BRAF
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • cifurtilimab (SEA-CD40)